Business Context and Reporting Period
This Form 8-K filing by CHF Solutions, Inc. (not Nuwellis, Inc.) reports on events occurring between March 8, 2019, and March 12, 2019. The filing details the entry into a material definitive agreement for a registered public offering and the subsequent closing of that offering.
Key Financial Metrics and Capital Structure
- Net Proceeds: Approximately $11.0 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Offering Price: $5.25 per Unit.
- Securities Issued:
- 455,178 shares of Common Stock (including 308,571 from the overallotment).
- 1,910,536 shares of Series G Convertible Preferred Stock.
- 2,365,714 Series 1 Warrants (5-year expiration).
- 2,365,714 Series 2 Warrants (18-month expiration or upon FDA pediatric clearance).
- Outstanding Equity (as of March 12, 2019):
- 968,623 shares of Common Stock.
- 535 shares of Series F Preferred Stock (convertible into 102,185 Common shares).
- 1,910,536 shares of Series G Preferred Stock (convertible into 1,910,536 Common shares).
Note: This filing does not provide revenue, profit, cash flow, or margin data.
Material Changes Versus Prior Period
The primary material change is the significant dilution and restructuring of the company's capital base due to the public offering. Specifically:
- Series F Anti-Dilution Adjustment: Due to the full-ratchet anti-dilution protection on Series F Convertible Preferred Stock, the conversion price was reduced from $29.68 to $5.25 (the public offering price) effective March 12, 2019.
- Capitalization Increase: The company moved from a pre-offering state to having over 1.9 million shares of Series G Preferred Stock and significant warrant obligations outstanding.
Guidance, Outlook, and Risks
- Lock-Up Period: The Company and its executive officers/directors are restricted from selling securities for 90 days following the Underwriting Agreement date.
- Warrant Call Provision: The Company may call for the cancellation of warrants if the stock price exceeds 300% of the exercise price ($5.25) for 30 consecutive trading days after 180 days post-closing, subject to volume and other conditions.
- Preferred Stock Conversion: The Company may force conversion of Series G Preferred Stock if the Common Stock price exceeds 300% of the conversion price for 20 of 30 consecutive trading days, subject to volume requirements.
- Beneficial Ownership Limits: Warrant and Preferred Stock holders are restricted from exercising or converting if it would result in beneficial ownership exceeding 4.99% (or 9.99% with notice).
Investor Verification Checklist
- Verify the exact net proceeds received ($11.0 million estimate) against the final closing statement.
- Confirm the impact of the Series F conversion price reduction ($29.68 to $5.25) on the total potential share count upon conversion.
- Review the specific terms of the Series 2 warrants regarding the FDA pediatric clearance trigger for expiration.
- Monitor the 90-day lock-up expiration date for potential selling pressure from insiders.
- Check the current trading volume and price to assess the likelihood of the Company exercising its call option on warrants or forced conversion of Series G stock.